|Videos|April 14, 2022
Combining Phenotypic Biomarkers and PET Imaging for Diagnosis and Treatment Selection
Author(s)Scott Tagawa, MD, MS, FACP, FASCO
A focused discussion on how phenotypic biomarkers and positron emission tomography (PET)-based imaging can be combined to diagnose and treat prostate cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Advertisement
Advertisement
Trending on Targeted Onc
1
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
2
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
5